OBJECTIVES: This study used proton magnetic resonance spectroscopy ((1)H MRS) to evaluate the in vivo effects of extended-release divalproex sodium on the glutamatergic system in adolescents with bipolar disorder, and to identify baseline neurochemical predictors of clinical remission. METHOD: Adolescents with bipolar disorder who were experiencing a manic or mixed episode (N = 25) were treated with open-label, extended-release divalproex (serum levels 85-125 μg/mL) and underwent (1)H MRS scanning at baseline (before treatment) and on days 7 and 28. Healthy comparison subjects (n = 15) also underwent (1)H MRS scanning at the same time points. Glutamate (Glu) and glutamate+glutamine (Glx) concentrations were measured in three voxels: anterior cingulate cortex (ACC), left ventrolateral prefrontal cortex (LVLPFC), and right ventrolateral prefrontal cortex (RVLPFC), and were compared between bipolar and healthy subjects. Within the bipolar subjects, Glu and Glx concentrations at baseline and each time point were also compared between remitters and nonremitters after divalproex treatment. RESULTS: At baseline, no differences in Glu or Glx concentrations between bipolar and healthy subjects were observed. Group (HC vs. BP) by time effects revealed an interaction for Glu in the ACC, and change over time effects for Glx were noted in the ACC in patients with bipolar disorder (increase from day 0 to day 7 and then a decrease from day 7 to day 28) but not in HC. Remitters had significantly lower baseline Glx concentrations in LVLPFC, and in remitters the change in LVLPFC Glu correlated with the change in YMRS score. CONCLUSIONS: Successful treatment of mania with divalproex may be predicted by lower baseline concentrations of Glx in the LVLPFC. In addition, in remitters, the degree of symptomatic improvement is related to the change in Glu concentrations in this region, suggesting that divalproex may work via modulation of the prefrontal glutamatergic system in youth with bipolar disorder.
OBJECTIVES: This study used proton magnetic resonance spectroscopy ((1)H MRS) to evaluate the in vivo effects of extended-release divalproex sodium on the glutamatergic system in adolescents with bipolar disorder, and to identify baseline neurochemical predictors of clinical remission. METHOD: Adolescents with bipolar disorder who were experiencing a manic or mixed episode (N = 25) were treated with open-label, extended-release divalproex (serum levels 85-125 μg/mL) and underwent (1)H MRS scanning at baseline (before treatment) and on days 7 and 28. Healthy comparison subjects (n = 15) also underwent (1)H MRS scanning at the same time points. Glutamate (Glu) and glutamate+glutamine (Glx) concentrations were measured in three voxels: anterior cingulate cortex (ACC), left ventrolateral prefrontal cortex (LVLPFC), and right ventrolateral prefrontal cortex (RVLPFC), and were compared between bipolar and healthy subjects. Within the bipolar subjects, Glu and Glx concentrations at baseline and each time point were also compared between remitters and nonremitters after divalproex treatment. RESULTS: At baseline, no differences in Glu or Glx concentrations between bipolar and healthy subjects were observed. Group (HC vs. BP) by time effects revealed an interaction for Glu in the ACC, and change over time effects for Glx were noted in the ACC in patients with bipolar disorder (increase from day 0 to day 7 and then a decrease from day 7 to day 28) but not in HC. Remitters had significantly lower baseline Glx concentrations in LVLPFC, and in remitters the change in LVLPFC Glu correlated with the change in YMRS score. CONCLUSIONS: Successful treatment of mania with divalproex may be predicted by lower baseline concentrations of Glx in the LVLPFC. In addition, in remitters, the degree of symptomatic improvement is related to the change in Glu concentrations in this region, suggesting that divalproex may work via modulation of the prefrontal glutamatergic system in youth with bipolar disorder.
Authors: B Geller; B Zimerman; M Williams; K Bolhofner; J L Craney; M P DelBello; C Soutullo Journal: J Am Acad Child Adolesc Psychiatry Date: 2001-04 Impact factor: 8.829
Authors: R A Kowatch; T Suppes; T J Carmody; J P Bucci; J H Hume; M Kromelis; G J Emslie; W A Weinberg; A J Rush Journal: J Am Acad Child Adolesc Psychiatry Date: 2000-06 Impact factor: 8.829
Authors: Kim M Cecil; Melissa P DelBello; Michele C Sellars; Stephen M Strakowski Journal: J Child Adolesc Psychopharmacol Date: 2003 Impact factor: 2.576
Authors: Robinder K Bhangoo; Catherine H Lowe; Frances S Myers; Julia Treland; Justin Curran; Kenneth E Towbin; Ellen Leibenluft Journal: J Child Adolesc Psychopharmacol Date: 2003 Impact factor: 2.576
Authors: Melissa P Delbello; Michael L Schwiers; H Lee Rosenberg; Stephen M Strakowski Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-10 Impact factor: 8.829
Authors: Manpreet K Singh; Booil Jo; Nancy E Adleman; Meghan Howe; Layla Bararpour; Ryan G Kelley; Daniel Spielman; Kiki D Chang Journal: Psychiatry Res Date: 2013-09-09 Impact factor: 3.222
Authors: Robert K McNamara; Jeffrey R Strawn; Max J Tallman; Jeffrey A Welge; L Rodrigo Patino; Thomas J Blom; Melissa P DelBello Journal: J Child Adolesc Psychopharmacol Date: 2020-03-11 Impact factor: 2.576
Authors: Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos Journal: Antioxid Redox Signal Date: 2019-02-01 Impact factor: 8.401
Authors: Elif M Sikoglu; Ana A Liso Navarro; Debra Starr; Yael Dvir; Benjamin Udoka Nwosu; Suzanne M Czerniak; Ryan C Rogan; Martha C Castro; Richard A E Edden; Jean A Frazier; Constance M Moore Journal: J Child Adolesc Psychopharmacol Date: 2015-06 Impact factor: 2.576
Authors: Paul E Croarkin; M Albert Thomas; John D Port; Joshua M Baruth; Doo-Sup Choi; Osama A Abulseoud; Mark A Frye Journal: Bipolar Disord Date: 2014-12-12 Impact factor: 6.744
Authors: D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw Journal: AJNR Am J Neuroradiol Date: 2014-02-20 Impact factor: 3.825
Authors: Paul E Croarkin; Paul A Nakonezny; Christopher A Wall; Lauren L Murphy; Shirlene M Sampson; Mark A Frye; John D Port Journal: Psychiatry Res Neuroimaging Date: 2015-11-27 Impact factor: 2.376